CN102058617B - 一种肝素钠维e凝胶及其制备方法 - Google Patents
一种肝素钠维e凝胶及其制备方法 Download PDFInfo
- Publication number
- CN102058617B CN102058617B CN2010106141753A CN201010614175A CN102058617B CN 102058617 B CN102058617 B CN 102058617B CN 2010106141753 A CN2010106141753 A CN 2010106141753A CN 201010614175 A CN201010614175 A CN 201010614175A CN 102058617 B CN102058617 B CN 102058617B
- Authority
- CN
- China
- Prior art keywords
- parts
- purified water
- vitamin
- gel
- heparin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229920000669 heparin Polymers 0.000 title claims abstract description 48
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 title claims abstract description 39
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 title claims abstract description 38
- 235000019165 vitamin E Nutrition 0.000 title claims abstract description 20
- 239000011709 vitamin E Substances 0.000 title claims abstract description 20
- 229930003427 Vitamin E Natural products 0.000 title claims abstract description 19
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 title claims abstract description 19
- 229940046009 vitamin E Drugs 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 238000001879 gelation Methods 0.000 title description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims abstract description 52
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 35
- 239000008213 purified water Substances 0.000 claims abstract description 34
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims abstract description 26
- 235000017557 sodium bicarbonate Nutrition 0.000 claims abstract description 26
- 238000003756 stirring Methods 0.000 claims abstract description 24
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims abstract description 17
- 239000002994 raw material Substances 0.000 claims abstract description 11
- 238000001914 filtration Methods 0.000 claims abstract description 8
- 229960001008 heparin sodium Drugs 0.000 claims description 32
- 239000007864 aqueous solution Substances 0.000 claims description 19
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 14
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 claims description 14
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 14
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 13
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 13
- 239000000706 filtrate Substances 0.000 claims description 12
- 229940088594 vitamin Drugs 0.000 claims description 10
- 229930003231 vitamin Natural products 0.000 claims description 10
- 235000013343 vitamin Nutrition 0.000 claims description 10
- 239000011782 vitamin Substances 0.000 claims description 10
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 10
- CXQXSVUQTKDNFP-UHFFFAOYSA-N octamethyltrisiloxane Chemical class C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 claims description 9
- 230000008961 swelling Effects 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- 229940008099 dimethicone Drugs 0.000 claims description 5
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 5
- 239000000758 substrate Substances 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 239000003292 glue Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 238000006386 neutralization reaction Methods 0.000 claims description 2
- 238000007872 degassing Methods 0.000 claims 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 claims 1
- 208000010445 Chilblains Diseases 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 10
- 206010000496 acne Diseases 0.000 abstract description 9
- 208000002874 Acne Vulgaris Diseases 0.000 abstract description 8
- 206010008570 Chloasma Diseases 0.000 abstract description 7
- 208000003351 Melanosis Diseases 0.000 abstract description 7
- 208000017520 skin disease Diseases 0.000 abstract description 3
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 abstract 3
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 abstract 3
- 229940049638 carbomer homopolymer type c Drugs 0.000 abstract 2
- 229940043234 carbomer-940 Drugs 0.000 abstract 2
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 abstract 2
- 229940083037 simethicone Drugs 0.000 abstract 2
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 22
- 210000003491 skin Anatomy 0.000 description 15
- 238000012360 testing method Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 5
- 239000000047 product Substances 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- 206010040882 skin lesion Diseases 0.000 description 3
- 231100000444 skin lesion Toxicity 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 206010015218 Erythema multiforme Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 208000006193 Pulmonary infarction Diseases 0.000 description 1
- 206010040849 Skin fissures Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 230000007575 pulmonary infarction Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010106141753A CN102058617B (zh) | 2010-12-30 | 2010-12-30 | 一种肝素钠维e凝胶及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010106141753A CN102058617B (zh) | 2010-12-30 | 2010-12-30 | 一种肝素钠维e凝胶及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102058617A CN102058617A (zh) | 2011-05-18 |
CN102058617B true CN102058617B (zh) | 2012-07-25 |
Family
ID=43994242
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010106141753A Expired - Fee Related CN102058617B (zh) | 2010-12-30 | 2010-12-30 | 一种肝素钠维e凝胶及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102058617B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107088173A (zh) * | 2016-06-13 | 2017-08-25 | 北京国济众芳中医药研究所 | 用于预防和缓解老年皮肤皲裂的凝胶及其制备方法和用途 |
CN106138521A (zh) * | 2016-06-28 | 2016-11-23 | 郑州雷曼药业有限公司 | 一种疤痕修复凝胶及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1478485A (zh) * | 2003-06-04 | 2004-03-03 | 山东大学 | 含肝素类药物的脂质体软膏剂及其制备方法 |
CN1907255A (zh) * | 2005-08-02 | 2007-02-07 | 赵勤 | 微循环舒活素护肤霜 |
-
2010
- 2010-12-30 CN CN2010106141753A patent/CN102058617B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1478485A (zh) * | 2003-06-04 | 2004-03-03 | 山东大学 | 含肝素类药物的脂质体软膏剂及其制备方法 |
CN1907255A (zh) * | 2005-08-02 | 2007-02-07 | 赵勤 | 微循环舒活素护肤霜 |
Non-Patent Citations (2)
Title |
---|
罗云 等.局部注射肝素钠联合维生素E按摩佐治新生儿寒冷损伤综合征57例.《新医学》.2008,第39卷(第4期),第250-251页. * |
高胜旗.肝素钠乳膏治疗冻疮.《食品与药品》.2005,第7卷(第11A期),第69页. * |
Also Published As
Publication number | Publication date |
---|---|
CN102058617A (zh) | 2011-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008140200A1 (en) | External compositions for the skin | |
CN102078638A (zh) | 一种长效组合型伤口敷料及其制备方法 | |
EP0621038A1 (en) | Pharmaceutical compositions containing silicate polymers | |
CN104622897A (zh) | 一种治疗皮肤病的护肤液及其制备方法 | |
CN103083712A (zh) | 掺入有干细胞或其它生物活性物质的外科敷料 | |
CN104013878B (zh) | 一种治疗脚气的足浴药醋及其制备方法 | |
CN105726366B (zh) | 皮脂膜修复组合物 | |
KR20160116800A (ko) | 피부보습용 조성물 | |
CN102058617B (zh) | 一种肝素钠维e凝胶及其制备方法 | |
CN102579655B (zh) | 治疗口腔溃疡的中药外敷制剂 | |
JP2009269904A (ja) | 外傷、褥瘡の治療用漢方薬組成物及びその製剤の製造方法 | |
CN103007000A (zh) | 一种治疗烧烫伤、创疡的新药及制备方法 | |
CN108078868B (zh) | 一种用于护肤品的抗过敏组合物 | |
CN100360141C (zh) | 小牛血清去蛋白凝胶和小牛血清去蛋白眼用凝胶 | |
CN113940896B (zh) | 含维a醇的抗衰肌肤修复液及其制备方法 | |
RU2548794C2 (ru) | Ингибитор эластазы | |
CN107569453A (zh) | 一种含蛋黄油具有修复冻烫伤及湿疹的抗衰小黄乳制备方法和应用 | |
CN108743891A (zh) | 一种纯天然活血化瘀止痛富氢药物组合物及其制备方法与应用 | |
CN112386531A (zh) | 一种皂荚低聚糖面膜及其制备方法 | |
CN101897693A (zh) | 儿茶素类化合物或含其的植物提取物的应用及药物组合物 | |
CN108310098A (zh) | 一种治疗痤疮的组合药物及其制备方法 | |
CN106913561B (zh) | 牛磺酸螯合钙在制备经皮吸收制剂中的应用 | |
KR20100111061A (ko) | 상처 치료용 조성물 | |
KR102420354B1 (ko) | 순환 활성 로션 조성물 및 그 제조방법 | |
CN111840448B (zh) | 防皲裂复方中药脂质体的制备方法及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: YUNNAN CONBA PLANT EXTRACTS CO., LTD. Free format text: FORMER OWNER: XIONGYE PHARMACEUTICAL INDUSTRY CO., LTD., YUNNAN Effective date: 20121113 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20121113 Address after: 655000 West Road, Qujing economic and Technological Development Zone, Yunnan Patentee after: Yunnan Conba Plant Extracts Co., Ltd. Address before: 655000, Yunnan, Qujing, Yunnan Qujing economic and Technological Development Zone, Rui West Road Patentee before: Xiongye Pharmaceutical Industry Co., Ltd., Yunnan |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160204 Address after: 650217 Yunnan city of Kunming Province Economic and Technological Development Zone No. 1 and Taolu Patentee after: Yunan Xitao Green Pharmaceutical Co., Ltd. Address before: 655000 West Road, Qujing economic and Technological Development Zone, Yunnan Patentee before: Yunnan Conba Plant Extracts Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120725 Termination date: 20161230 |
|
CF01 | Termination of patent right due to non-payment of annual fee |